A beneficial deal
31/08/24 -"We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced pipeline assets (all the mRNA vaccine candidates ..."
Pages
52
Language
English
Published on
31/08/24
You may also be interested by these reports :
31/08/24
We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced ...
22/08/24
Better than consensus, as we expected – Outlook confirmed
21/08/24
The Q2 results exceeded expectations, supported by the strong showing from Lundbeck’s four key brands. Consequently, the management upgraded its 2024 ...
20/08/24
CureVac’s management could have taken the opportunity to clarify the news about the potentially planned departure of the current CFO, but the company ...